Sequoia Financial Advisors LLC Acquires 67,586 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Sequoia Financial Advisors LLC increased its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 432.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,229 shares of the company’s stock after purchasing an additional 67,586 shares during the period. Sequoia Financial Advisors LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,314,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. POM Investment Strategies LLC boosted its position in Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after buying an additional 1,820 shares during the period. Allworth Financial LP lifted its stake in shares of Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock valued at $41,000 after acquiring an additional 2,230 shares during the last quarter. Sierra Ocean LLC purchased a new stake in Dr. Reddy’s Laboratories during the 4th quarter valued at about $43,000. Independence Bank of Kentucky grew its position in Dr. Reddy’s Laboratories by 400.0% during the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after acquiring an additional 2,220 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Dr. Reddy’s Laboratories in the 3rd quarter worth approximately $60,000. Institutional investors own 3.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on RDY shares. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th.

Dr. Reddy’s Laboratories Trading Up 0.2 %

NYSE RDY opened at $12.69 on Friday. The stock has a market cap of $10.60 billion, a P/E ratio of 20.21 and a beta of 0.48. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $12.50 and a fifty-two week high of $16.89. The stock has a 50 day simple moving average of $13.87 and a two-hundred day simple moving average of $14.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.